InMode (NASDAQ:INMD - Get Free Report) announced its earnings results on Monday. The healthcare company reported $0.31 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.45 by ($0.14), Briefing.com reports. The business had revenue of $77.87 million during the quarter, compared to the consensus estimate of $82.21 million. InMode had a net margin of 45.91% and a return on equity of 18.25%. The company's revenue was down 3.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.32 EPS.
InMode Stock Up 4.3 %
Shares of NASDAQ INMD traded up $0.60 during midday trading on Thursday, reaching $14.70. 1,722,242 shares of the company were exchanged, compared to its average volume of 1,198,199. The stock's 50-day moving average price is $17.07 and its 200-day moving average price is $17.59. The stock has a market cap of $1.02 billion, a P/E ratio of 6.26 and a beta of 1.96. InMode has a one year low of $13.68 and a one year high of $19.85.
Wall Street Analyst Weigh In
Several equities research analysts recently weighed in on INMD shares. Robert W. Baird cut shares of InMode from an "outperform" rating to a "neutral" rating and cut their price objective for the stock from $22.00 to $16.00 in a research report on Monday. Jefferies Financial Group cut their price objective on shares of InMode from $16.00 to $15.00 and set a "hold" rating for the company in a research report on Monday, April 14th. Needham & Company LLC reaffirmed a "hold" rating on shares of InMode in a research report on Monday. Baird R W cut shares of InMode from a "strong-buy" rating to a "hold" rating in a research report on Monday. Finally, BTIG Research cut shares of InMode from a "buy" rating to a "neutral" rating in a research report on Tuesday. Seven equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $18.54.
Read Our Latest Research Report on INMD
InMode Company Profile
(
Get Free Report)
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.
Further Reading
Before you consider InMode, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InMode wasn't on the list.
While InMode currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
